Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4268459 | 0.86 | SLC2A1 (0.64) | SLC2A1KCNH2 | |
| SCHEMBL5771529 | 0.86 | SLC2A1 (0.49) | SLC2A1L3MBTL1KCNH2LMNAGAA | |
| SCHEMBL5799819 | 0.86 | SLC2A1 (0.49) | SLC2A1L3MBTL1KCNH2LMNAGAA | |
| SCHEMBL5776914 | 0.85 | MEN1 (0.40) | SLC2A1L3MBTL1KCNH2LMNAHTT | |
| SCHEMBL5754730 | 0.78 | SLC2A1 (0.56) | SLC2A1KCNH2 | |
| SCHEMBL4270115 | 0.77 | SLC2A1 (0.64) | SLC2A1KCNH2 | |
| SCHEMBL4269328 | 0.77 | SLC2A1 (0.66) | SLC2A1KCNH2 | |
| SCHEMBL5773715 | 0.76 | SLC2A1 (0.39) | SLC2A1L3MBTL1KCNH2 | |
| SCHEMBL5757405 | 0.75 | SLC2A1 (0.59) | SLC2A1KCNH2 | |
| SCHEMBL6485492 | 0.74 | SLC2A1 (0.53) | SLC2A1KCNH2LMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | claimed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1343780-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | claimed |
| WO-2002050061-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | claimed |
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | SLC2A1 2617/4885L3MBTL1 566/4885KCNH2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.